Nguyen Mathew L, Pirzada Mustafa H, Shapiro Michael A
Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Florida, Gainesville, Florida.
J Pediatr Pharmacol Ther. 2013 Oct;18(4):311-4. doi: 10.5863/1551-6776-18.4.311.
Obesity in children and adolescents is a growing epidemic in the United States, and physicians are increasingly looking for safe and effective treatments. In recent years, pharmacologic treatment has been considered for severe and refractory cases of adolescent obesity. We present a case of an obese adolescent who presented to an inpatient psychiatric unit with a body mass index (BMI) of 37.8 (>98th percentile for age). He was started on zonisamide for the purposes of weight loss, and a steady decrease in weight and BMI was noted through 4 months of outpatient follow-up. During this time, the patient's weight decreased from 126.8 kg to 106.2 kg, a 20.6-kg loss, representing a 16.25% reduction in weight. His most recent BMI decreased to 31.7 (96th percentile for age). We discuss the potential use of zonisamide for weight loss in adolescents, considering the potential risks and benefits.
儿童和青少年肥胖在美国正日益成为一种流行病,医生们越来越多地寻求安全有效的治疗方法。近年来,对于青少年严重和难治性肥胖病例,已考虑采用药物治疗。我们报告一例肥胖青少年病例,该患者因体重指数(BMI)为37.8(>年龄的第98百分位数)入住住院精神科病房。为了减肥,他开始服用唑尼沙胺,在4个月的门诊随访中,体重和BMI持续下降。在此期间,患者体重从126.8千克降至106.2千克,减重20.6千克,体重减轻了16.25%。他最近的BMI降至31.7(年龄的第96百分位数)。我们在考虑潜在风险和益处的情况下,讨论了唑尼沙胺在青少年减肥中的潜在用途。